(Q38058383)
Statements
Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses (English)
L Crathorne
T Jones-Hughes
L Osipenko
M Venkatachalam
C Rudin
O Ukoumunne